Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FXIII Concentrate in Congenital Factor XIII Deficiency
NCT00945906Phase 3Completed
- Sponsor
- CSL Limited
- Start
- Sep 2009
- Primary completion
- Aug 2011
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of Factor XIII (human) in congenital factor XIII deficiency, sponsored by CSL Limited. Primary endpoint: Adverse Events up to 2 years. Started Sep 2009; status: completed.
02
Drugs
Factor XIII (human)
03
Conditions
congenital factor XIII deficiency
Beyond the preview
Go deeper on NCT00945906.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00945906.